These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 28699047

  • 1. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
    Gupta F, Karabin B, Mehdirad A.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):15-16. PubMed ID: 28699047
    [No Abstract] [Full Text] [Related]

  • 2. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP, Claassen D, Mehdirad A.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract] [Full Text] [Related]

  • 3. Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.
    Mehdirad A, Karabin B, Gupta F.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):25-27. PubMed ID: 28634637
    [No Abstract] [Full Text] [Related]

  • 4. Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Claassen D, Lew M.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):13-14. PubMed ID: 28631224
    [No Abstract] [Full Text] [Related]

  • 5. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
    Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH.
    Clin Neuropharmacol; 2016 Jul; 39(5):220-6. PubMed ID: 27332626
    [Abstract] [Full Text] [Related]

  • 6. Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
    Goodman BP, Gupta F.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):21-23. PubMed ID: 28631222
    [No Abstract] [Full Text] [Related]

  • 7. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
    Vernino S, Claassen D.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):33-34. PubMed ID: 28674868
    [No Abstract] [Full Text] [Related]

  • 8. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
    Kremens D, Lew M, Claassen D, Goodman BP.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):29-31. PubMed ID: 28674867
    [No Abstract] [Full Text] [Related]

  • 9. Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Lew M, Kremens D.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):5-7. PubMed ID: 28674866
    [No Abstract] [Full Text] [Related]

  • 10. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

  • 11. Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension.
    Vernino S, Lew M, Kremens D.
    Clin Auton Res; 2017 Jul 15; 27(Suppl 1):35-37. PubMed ID: 28623420
    [No Abstract] [Full Text] [Related]

  • 12. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA, Hewitt LA, Isaacson S.
    J Parkinsons Dis; 2014 Jul 15; 4(1):57-65. PubMed ID: 24326693
    [Abstract] [Full Text] [Related]

  • 13. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Jul 15; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 14. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 15. Droxidopa (Northera) for neurogenic orthostatic hypotension.
    Med Lett Drugs Ther; 2015 Jun 22; 57(1471):92-3. PubMed ID: 26079764
    [No Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA.
    J Med Econ; 2016 Jun 22; 19(5):515-25. PubMed ID: 26710315
    [Abstract] [Full Text] [Related]

  • 17. Droxidopa reduces postural sway in Parkinson disease patients with orthostatic hypotension.
    Marsili L, Duque KR, Sturchio A, Sobrero G, Premoli I, Dwivedi AK, Espay AJ, Merola A.
    Parkinsonism Relat Disord; 2022 Jun 22; 99():62-64. PubMed ID: 35605513
    [Abstract] [Full Text] [Related]

  • 18. Persistent unexplained chest pain and dyspnea in a patient with coronary artery disease: a case report.
    Mobarek SK.
    BMC Cardiovasc Disord; 2020 Feb 04; 20(1):54. PubMed ID: 32019498
    [Abstract] [Full Text] [Related]

  • 19. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 04; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 20. Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease.
    Gupta F, Kremens D, Vernino S, Karabin B.
    Clin Auton Res; 2017 Jul 04; 27(Suppl 1):9-11. PubMed ID: 28699048
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.